Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma

Christine G. Gourin, William H. Moretz, Paul M. Weinberger, Zhong Sheng Xia, Zhongmin Liu, David J. Terris, Bao Ling Adam

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To determine the sensitivity and specificity of surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) assay for head and neck squamous cell carcinoma (HNSCC) disease surveillance. Design: The SELDI-TOF-MS serum protein profiles of patients with HNSCC were analyzed to determine the sensitivity and specificity of the SELDI assay for HNSCC detection following definitive treatment. Setting: Academic research. Patients: Thirty-two patients with previously untreated HNSCC. Intervention: Serum samples were collected prospectively at 3-month intervals following treatment during a 24-month follow-up period. Main Outcome Measures: Ninety-three serum samples were analyzed. Results: The SELDI-TOF-MS identified protein peaks in the range of 0 to 100 kDa. Classification tree analysis based on peak expression distinguished pretreatment from 6-month posttreatment samples with 75.0% sensitivity and 87.5% specificity. Samples collected at 3 months following treatment did not significantly differ from pretreatment samples. Serum samples from patients who were disease free at 6 months or longer following treatment differed from matched pretreatment samples by the overexpression of a protein peak at 6495 Da, while serum samples from patients with recurrence differed from matched pretreatment samples by the underexpression of a protein peak at 4493 Da. Conclusions: Proteomic analysis of serum protein profiles distinguishes pretreatment and posttreatment samples from patients with HNSCC with a high degree of sensitivity and specificity. After 6 months, serum protein profiles seem to have distinct differences in peak expression based on disease status. Further investigation of the clinical usefulness of this technology in HNSCC detection and surveillance is warranted.

Original languageEnglish (US)
Pages (from-to)1125-1130
Number of pages6
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume133
Issue number11
DOIs
StatePublished - Nov 1 2007

Fingerprint

Blood Proteins
Sensitivity and Specificity
Mass Spectrometry
Lasers
Serum
Therapeutics
Proteins
Proteomics
Carcinoma, squamous cell of head and neck
Outcome Assessment (Health Care)
Technology
Recurrence
Research

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma. / Gourin, Christine G.; Moretz, William H.; Weinberger, Paul M.; Xia, Zhong Sheng; Liu, Zhongmin; Terris, David J.; Adam, Bao Ling.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 133, No. 11, 01.11.2007, p. 1125-1130.

Research output: Contribution to journalArticle

Gourin, Christine G. ; Moretz, William H. ; Weinberger, Paul M. ; Xia, Zhong Sheng ; Liu, Zhongmin ; Terris, David J. ; Adam, Bao Ling. / Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma. In: Archives of Otolaryngology - Head and Neck Surgery. 2007 ; Vol. 133, No. 11. pp. 1125-1130.
@article{48e15b3291ef42ef912708b776e87cfd,
title = "Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma",
abstract = "Objective: To determine the sensitivity and specificity of surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) assay for head and neck squamous cell carcinoma (HNSCC) disease surveillance. Design: The SELDI-TOF-MS serum protein profiles of patients with HNSCC were analyzed to determine the sensitivity and specificity of the SELDI assay for HNSCC detection following definitive treatment. Setting: Academic research. Patients: Thirty-two patients with previously untreated HNSCC. Intervention: Serum samples were collected prospectively at 3-month intervals following treatment during a 24-month follow-up period. Main Outcome Measures: Ninety-three serum samples were analyzed. Results: The SELDI-TOF-MS identified protein peaks in the range of 0 to 100 kDa. Classification tree analysis based on peak expression distinguished pretreatment from 6-month posttreatment samples with 75.0{\%} sensitivity and 87.5{\%} specificity. Samples collected at 3 months following treatment did not significantly differ from pretreatment samples. Serum samples from patients who were disease free at 6 months or longer following treatment differed from matched pretreatment samples by the overexpression of a protein peak at 6495 Da, while serum samples from patients with recurrence differed from matched pretreatment samples by the underexpression of a protein peak at 4493 Da. Conclusions: Proteomic analysis of serum protein profiles distinguishes pretreatment and posttreatment samples from patients with HNSCC with a high degree of sensitivity and specificity. After 6 months, serum protein profiles seem to have distinct differences in peak expression based on disease status. Further investigation of the clinical usefulness of this technology in HNSCC detection and surveillance is warranted.",
author = "Gourin, {Christine G.} and Moretz, {William H.} and Weinberger, {Paul M.} and Xia, {Zhong Sheng} and Zhongmin Liu and Terris, {David J.} and Adam, {Bao Ling}",
year = "2007",
month = "11",
day = "1",
doi = "10.1001/archotol.133.11.1125",
language = "English (US)",
volume = "133",
pages = "1125--1130",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma

AU - Gourin, Christine G.

AU - Moretz, William H.

AU - Weinberger, Paul M.

AU - Xia, Zhong Sheng

AU - Liu, Zhongmin

AU - Terris, David J.

AU - Adam, Bao Ling

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Objective: To determine the sensitivity and specificity of surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) assay for head and neck squamous cell carcinoma (HNSCC) disease surveillance. Design: The SELDI-TOF-MS serum protein profiles of patients with HNSCC were analyzed to determine the sensitivity and specificity of the SELDI assay for HNSCC detection following definitive treatment. Setting: Academic research. Patients: Thirty-two patients with previously untreated HNSCC. Intervention: Serum samples were collected prospectively at 3-month intervals following treatment during a 24-month follow-up period. Main Outcome Measures: Ninety-three serum samples were analyzed. Results: The SELDI-TOF-MS identified protein peaks in the range of 0 to 100 kDa. Classification tree analysis based on peak expression distinguished pretreatment from 6-month posttreatment samples with 75.0% sensitivity and 87.5% specificity. Samples collected at 3 months following treatment did not significantly differ from pretreatment samples. Serum samples from patients who were disease free at 6 months or longer following treatment differed from matched pretreatment samples by the overexpression of a protein peak at 6495 Da, while serum samples from patients with recurrence differed from matched pretreatment samples by the underexpression of a protein peak at 4493 Da. Conclusions: Proteomic analysis of serum protein profiles distinguishes pretreatment and posttreatment samples from patients with HNSCC with a high degree of sensitivity and specificity. After 6 months, serum protein profiles seem to have distinct differences in peak expression based on disease status. Further investigation of the clinical usefulness of this technology in HNSCC detection and surveillance is warranted.

AB - Objective: To determine the sensitivity and specificity of surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) assay for head and neck squamous cell carcinoma (HNSCC) disease surveillance. Design: The SELDI-TOF-MS serum protein profiles of patients with HNSCC were analyzed to determine the sensitivity and specificity of the SELDI assay for HNSCC detection following definitive treatment. Setting: Academic research. Patients: Thirty-two patients with previously untreated HNSCC. Intervention: Serum samples were collected prospectively at 3-month intervals following treatment during a 24-month follow-up period. Main Outcome Measures: Ninety-three serum samples were analyzed. Results: The SELDI-TOF-MS identified protein peaks in the range of 0 to 100 kDa. Classification tree analysis based on peak expression distinguished pretreatment from 6-month posttreatment samples with 75.0% sensitivity and 87.5% specificity. Samples collected at 3 months following treatment did not significantly differ from pretreatment samples. Serum samples from patients who were disease free at 6 months or longer following treatment differed from matched pretreatment samples by the overexpression of a protein peak at 6495 Da, while serum samples from patients with recurrence differed from matched pretreatment samples by the underexpression of a protein peak at 4493 Da. Conclusions: Proteomic analysis of serum protein profiles distinguishes pretreatment and posttreatment samples from patients with HNSCC with a high degree of sensitivity and specificity. After 6 months, serum protein profiles seem to have distinct differences in peak expression based on disease status. Further investigation of the clinical usefulness of this technology in HNSCC detection and surveillance is warranted.

UR - http://www.scopus.com/inward/record.url?scp=36348967765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348967765&partnerID=8YFLogxK

U2 - 10.1001/archotol.133.11.1125

DO - 10.1001/archotol.133.11.1125

M3 - Article

C2 - 18025317

AN - SCOPUS:36348967765

VL - 133

SP - 1125

EP - 1130

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 11

ER -